Your browser doesn't support javascript.
loading
Emerging roles of protein O-GlcNAcylation in cardiovascular diseases: Insights and novel therapeutic targets.
Bolanle, Israel Olapeju; Riches-Suman, Kirsten; Williamson, Ritchie; Palmer, Timothy M.
Afiliação
  • Bolanle IO; Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.
  • Riches-Suman K; School of Chemistry and Bioscience, University of Bradford, Bradford BD7 1DP, UK.
  • Williamson R; School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, UK.
  • Palmer TM; Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull HU6 7RX, UK. Electronic address: Tim.Palmer@hyms.ac.uk.
Pharmacol Res ; 165: 105467, 2021 03.
Article em En | MEDLINE | ID: mdl-33515704
ABSTRACT
Cardiovascular diseases (CVDs) are the leading cause of death globally. While the major focus of pharmacological and non-pharmacological interventions has been on targeting disease pathophysiology and limiting predisposing factors, our understanding of the cellular and molecular mechanisms underlying the pathogenesis of CVDs remains incomplete. One mechanism that has recently emerged is protein O-GlcNAcylation. This is a dynamic, site-specific reversible post-translational modification of serine and threonine residues on target proteins and is controlled by two enzymes O-linked ß-N-acetylglucosamine transferase (OGT) and O-linked ß-N-acetylglucosaminidase (OGA). Protein O-GlcNAcylation alters the cellular functions of these target proteins which play vital roles in pathways that modulate vascular homeostasis and cardiac function. Through this review, we aim to give insights on the role of protein O-GlcNAcylation in cardiovascular diseases and identify potential therapeutic targets in this pathway for development of more effective medicines to improve patient outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Cardiovasculares / Doenças Cardiovasculares / Processamento de Proteína Pós-Traducional / Sistemas de Liberação de Medicamentos / Inibidores Enzimáticos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fármacos Cardiovasculares / Doenças Cardiovasculares / Processamento de Proteína Pós-Traducional / Sistemas de Liberação de Medicamentos / Inibidores Enzimáticos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article